Tackling Sleeping Sickness: Current and Promising Therapeutics and Treatment Strategies
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241512529 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Miebaka Jamabo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Biotechnology Innovation Centre, Rhodes University, Makhanda 6139, South Africa. Hauptthemen laut MEDLINE: Trypanosomiasis, African, COVID-19, Trypanosoma brucei brucei, Trypanosoma. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 299 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation, 2018 DAAD In-Region Scholarship, Pearson Young Scholarship.
Abstract (Originalsprache)
Human African trypanosomiasis is a neglected tropical disease caused by the extracellular protozoan parasite Trypanosoma brucei, and targeted for eradication by 2030. The COVID-19 pandemic contributed to the lengthening of the proposed time frame for eliminating human African trypanosomiasis as control programs were interrupted. Armed with extensive antigenic variation and the depletion of the B cell population during an infectious cycle, attempts to develop a vaccine have remained unachievable. With the absence of a vaccine, control of the disease has relied heavily on intensive screening measures and the use of drugs. The chemotherapeutics previously available for disease management were plagued by issues such as toxicity, resistance, and difficulty in administration. The approval of the latest and first oral drug, fexinidazole, is a major chemotherapeutic achievement for the treatment of human African trypanosomiasis in the past few decades. Timely and accurate diagnosis is essential for effective treatment, while poor compliance and resistance remain outstanding challenges. Drug discovery is on-going, and herein we review the recent advances in anti-trypanosomal drug discovery, including novel potential drug targets. The numerous challenges associated with disease eradication will also be addressed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Biotechnology Innovation Centre, Rhodes University, Makhanda 6139, South Africa.
- Department of Biochemistry and Microbiology, Biomedical Biotechnology Research Centre (BioBRU), Rhodes University, Makhanda 6139, South Africa.
ORCID-Profile: Miebaka Jamabo, Maduma Mahlalela, Adrienne L Edkins, Aileen Boshoff
Förderung
- National Research Foundation
- 2018 DAAD In-Region Scholarship
- Pearson Young Scholarship
- South African Research Chairs Initiative (SARChI) of the Department of Science and Innovation (DSI) and National Research Foundation of South Africa (NRF)
- NRF Competitive Grants for Rated Researchers (CPRR)
- Rhodes University
Zitieren
APA
Jamabo, M., Mahlalela, M., Edkins, A. L., & Boshoff, A. (2023). Tackling Sleeping Sickness: Current and Promising Therapeutics and Treatment Strategies. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241512529
Vancouver
Jamabo M, Mahlalela M, Edkins AL, Boshoff A. Tackling Sleeping Sickness: Current and Promising Therapeutics and Treatment Strategies. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241512529
BibTeX
@article{Jamabo2023,
author = {Jamabo, Miebaka and Mahlalela, Maduma and Edkins, Adrienne L and Boshoff, Aileen},
title = {Tackling Sleeping Sickness: Current and Promising Therapeutics and Treatment Strategies},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241512529}
}
EUVIMED